Pages that link to "Q35974328"

The following pages link to Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival (Q35974328):

Displaying 20 items.

• Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis (Q26741263) (← links)
• Circulating biomarkers in advanced renal cell carcinoma: clinical applications (Q27023770) (← links)
• Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma (Q28067482) (← links)
• Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. (Q34899343) (← links)
• A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma (Q35747277) (← links)
• The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer (Q36420167) (← links)
• Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. (Q37470058) (← links)
• Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays (Q37516483) (← links)
• Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors (Q38116001) (← links)
• Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma (Q40132819) (← links)
• Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma (Q41091919) (← links)
• Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials (Q44272543) (← links)
• The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer (Q46358843) (← links)
• Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells of patients with differentiated thyroid carcinoma (Q50318735) (← links)
• Interleukin-6 induces drug resistance in renal cell carcinoma (Q58119454) (← links)
• Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells (Q58801106) (← links)
• Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib (Q83825588) (← links)
• Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer (Q86934356) (← links)
• Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer (Q89373189) (← links)
• Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma (Q91910929) (← links)